HBV infection and hepatitis B in patients treated with anti-CD20 monoclonal antibodies Review article
Article Sidebar
Main Article Content
Abstract
In the 21st century, there was a significant breakthrough in the treatment of many neoplasms, autoimmune diseases and chronic inflammations due to the introduction of monoclonal antibodies into therapeutic regimens. Among them, some of the most frequently used are anti-TNF and anti-CD20 antibodies. Particularly related to the latter is the issue of reactivation of HBV infection, which can lead to fulminant inflammation and liver failure, and in some cases even death of the patient. Nevertheless, physicians who use the above-mentioned medicines have diagnostic tools at their disposal to determine the status of HBV infection, as well as vaccinations and drugs that can be used to minimize the risk of HBV reactivation with all its consequences. In this paper, I present the basic aspects of HBV infection that every doctor dealing with anti-CD20 therapy should know, as well as the procedures for dealing with a patient qualified for such therapy.
Article Details
Copyright © by Medical Education. All rights reserved.
References
2. Patullo V. Prevention of Hepatitis B reactivation in the setting of immunosuppression. Clin Molec Hepatol. 2016; 22: 219.
3. Kusumoto S, Arcaini L, Hong X et al. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood. 2019; 133(2): 137-46.
4. Programy lekowe NFZ – program B.106.
5. Grabarczyk P, Kopacz A, Sulkowska E et al. Blood donors screening for blood born viruses in Poland. Przegl Epidemiol. 2015; 69(3): 473-7, 591-5.
6. Niedziela N, Zimnol A, Lubczyński M et al. Ocrelizumab therapy in patients with anti-HBc antibodies – a preliminary study. Pol Merkur Lekarski. 2023; 53(3): 189-93.
7. Jaroszewicz J, Pawłowska M, Simon K et al. Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA. Expert Rev Anti Infect Ther. 2020; 18(10): 1045-54.
8. Flisiak R (ed). Choroby zakaźne i pasożytnicze. Tom III. Wydanie I, Czelej sp. z.o.o., Lublin 2020: 665.
9. Kramvis A, Chang K, Dandri M et al. A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook. Nat Rev Gastroenterol Hepatol. 2022; 19(11): 727-45.
10. Cai Y, Yin W. The Multiple Functions of B Cells in Chronic HBV Infection. Front Immunol. 2020; 11: 582292.
11. Dumolard L, Aspord C, Marche P et al. Immune checkpoints on T and NK cells in the context of HBV infection: Landscape, pathophysiology and therapeutic exploitation. Front Immunol. 2023; 14: 1148111.
12. Onorato L, Pisaturo M, Camaioni C et al. Risk and Prevention of Hepatitis B Virus Reactivation during Immunosuppression for Non-Oncological Diseases. J Clin Med. 2021; 10(21): 5201.
13. Engerix-Chpl – GSK 13-01-2022.
14. Program szczepień ochronnych na rok 2023.
15. Yang S, Tian G, Cui Y et al. Factors influencing immunologic response to hepatitis B vaccine in adults. Sci Rep. 2016; 6: 27251.
16. Pawłowska M, Flisiak R, Gil L et al. Prophylaxis of hepatitis B virus (HBV) infection reactivation – recommendations of the Working Group for prevention of HBV reactivation. Clin Exp Hepatol. 2019; 5(3): 195-202.
17. Cholongitas E, Haidich AB, Apostolidou-Kiouti F et al. Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review. Ann Gastroenterol. 2018; 31(4): 480-90.
18. Ciardi MR, Iannetta M, Zingaropoli MA et al. Reactivation of Hepatitis B Virus with Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis. Open Forum Infect Dis. 2018; 6(1): ofy356.